Prospective evaluation of contrast-enhanced ultrasound of breast BI-RADS 3-5 lesions.


Journal

BMC medical imaging
ISSN: 1471-2342
Titre abrégé: BMC Med Imaging
Pays: England
ID NLM: 100968553

Informations de publication

Date de publication:
17 06 2020
Historique:
received: 03 12 2019
accepted: 10 06 2020
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 29 6 2021
Statut: epublish

Résumé

To determine the benefit of contrast-enhanced ultrasound (CEUS) in the assessment of breast lesions. A standardized contrast-enhanced ultrasound was performed in 230 breast lesions classified as BI-RADS category 3 to 5. All lesions were subjected to qualitative and quantitative analysis. MVI (MicroVascular Imaging) technique was used to derive qualitative analysis parameters; blood perfusion of the lesions was assessed (perfusion homogeneity, type of vascularization, enhancement degree). Quantitative analysis was conducted to estimate perfusion changes in the lesions within drawn regions of interest (ROI); parameters TTP (time to peak), PI (peak intensity), WIS (wash in slope), AUC (area under curve) were obtained from time intensity (TI) curves. Acquired data were statistically analyzed to assess the ability of each parameter to differentiate between malignant and benign lesions. The combination of parameters was also evaluated for the possibility of increasing the overall diagnostic accuracy. Biological nature of the lesions was verified by a pathologist. Benign lesions without histopathological verification (BI-RADS 3) were followed up for at least 24 months. Out of 230 lesions, 146 (64%) were benign, 67 (29%) were malignant, 17 (7%) lesions were eliminated. Malignant tumors showed statistically significantly lower TTP parameters (sensitivity 77.6%, specificity 52.7%) and higher WIS values (sensitivity 74.6%, specificity 66.4%) than benign tumors. Enhancement degree also proved to be statistically well discriminating as 55.2% of malignant lesions had a rich vascularity (sensitivity 89.6% and specificity 48.6%). The combination of quantitative analysis parameters (TTP, WIS) with enhancement degree did not result in higher accuracy in distinguishing between malignant and benign breast lesions. We have demonstrated that contrast-enhanced breast ultrasound has the potential to distinguish between malignant and benign lesions. In particular, this method could help to differentiate lesions BI-RADS category 3 and 4 and thus reduce the number of core-cut biopsies performed in benign lesions. Qualitative analysis, despite its subjective element, appeared to be more beneficial. A combination of quantitative and qualitative analysis did not increase the predictive capability of CEUS.

Sections du résumé

BACKGROUND
To determine the benefit of contrast-enhanced ultrasound (CEUS) in the assessment of breast lesions.
METHODS
A standardized contrast-enhanced ultrasound was performed in 230 breast lesions classified as BI-RADS category 3 to 5. All lesions were subjected to qualitative and quantitative analysis. MVI (MicroVascular Imaging) technique was used to derive qualitative analysis parameters; blood perfusion of the lesions was assessed (perfusion homogeneity, type of vascularization, enhancement degree). Quantitative analysis was conducted to estimate perfusion changes in the lesions within drawn regions of interest (ROI); parameters TTP (time to peak), PI (peak intensity), WIS (wash in slope), AUC (area under curve) were obtained from time intensity (TI) curves. Acquired data were statistically analyzed to assess the ability of each parameter to differentiate between malignant and benign lesions. The combination of parameters was also evaluated for the possibility of increasing the overall diagnostic accuracy. Biological nature of the lesions was verified by a pathologist. Benign lesions without histopathological verification (BI-RADS 3) were followed up for at least 24 months.
RESULTS
Out of 230 lesions, 146 (64%) were benign, 67 (29%) were malignant, 17 (7%) lesions were eliminated. Malignant tumors showed statistically significantly lower TTP parameters (sensitivity 77.6%, specificity 52.7%) and higher WIS values (sensitivity 74.6%, specificity 66.4%) than benign tumors. Enhancement degree also proved to be statistically well discriminating as 55.2% of malignant lesions had a rich vascularity (sensitivity 89.6% and specificity 48.6%). The combination of quantitative analysis parameters (TTP, WIS) with enhancement degree did not result in higher accuracy in distinguishing between malignant and benign breast lesions.
CONCLUSIONS
We have demonstrated that contrast-enhanced breast ultrasound has the potential to distinguish between malignant and benign lesions. In particular, this method could help to differentiate lesions BI-RADS category 3 and 4 and thus reduce the number of core-cut biopsies performed in benign lesions. Qualitative analysis, despite its subjective element, appeared to be more beneficial. A combination of quantitative and qualitative analysis did not increase the predictive capability of CEUS.

Identifiants

pubmed: 32552678
doi: 10.1186/s12880-020-00467-2
pii: 10.1186/s12880-020-00467-2
pmc: PMC7302394
doi:

Substances chimiques

Contrast Media 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

66

Subventions

Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : MMCI 00209805
Pays : International
Organisme : Ministerstvo Zdravotnictví Ceské Republiky
ID : MMCI 00209805
Pays : International

Références

Eur J Radiol. 2012 Dec;81(12):3890-9
pubmed: 23062280
Eur J Radiol. 2012 Apr;81(4):e444-50
pubmed: 21612882
J Ultrasound Med. 2007 Jun;26(6):807-15
pubmed: 17526612
Ann Transl Med. 2019 Nov;7(22):647
pubmed: 31930048
Clin Cancer Res. 2005 May 15;11(10):3647-53
pubmed: 15897560
Nature. 2005 Dec 15;438(7070):932-6
pubmed: 16355210
Eur J Radiol. 2010 Feb;73(2):288-93
pubmed: 19559551
Clin Cancer Res. 2003 Aug 15;9(9):3369-75
pubmed: 12960124
Clin Hemorheol Microcirc. 2020;74(4):463-473
pubmed: 31868661
Ultrasound Med Biol. 2014 Jan;40(1):11-7
pubmed: 24207087
J Ultrasound Med. 2007 Jun;26(6):757-62
pubmed: 17526607
J Ultrasound Med. 2019 Sep;38(9):2259-2273
pubmed: 30597640
Invest Radiol. 2019 May;54(5):257-264
pubmed: 30632985
Clin Hemorheol Microcirc. 2019;72(3):293-303
pubmed: 30856103
Klin Onkol. 2012;25(3):188-98
pubmed: 22724568
J Ultrasound Med. 2008 Jun;27(6):821-31
pubmed: 18499842
Eur J Radiol. 2014 Jul;83(7):1098-1105
pubmed: 24794865
Clin Breast Cancer. 2003 Dec;4(5):340-7
pubmed: 14715109
Ultraschall Med. 2007 Feb;28(1):57-62
pubmed: 17304413
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
Eur Radiol. 2013 Dec;23(12):3228-36
pubmed: 23821023
Cancer Manag Res. 2019 Mar 15;11:2163-2170
pubmed: 30936748

Auteurs

Eva Janu (E)

The Clinic of Radiology and Nuclear Medicine, The University Hospital Brno, Brno, Czech Republic.
The Clinic of Radiology and Nuclear Medicine, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Lucie Krikavova (L)

The Clinic of Radiology and Nuclear Medicine, The University Hospital Brno, Brno, Czech Republic.

Jirina Little (J)

The Clinic of Radiology and Nuclear Medicine, The University Hospital Brno, Brno, Czech Republic.

Karel Dvorak (K)

The Clinic of Radiology and Nuclear Medicine, The University Hospital Brno, Brno, Czech Republic.

Dagmar Brancikova (D)

The Clinic of Internal Medicine - Haematology and Oncology, The University Hospital Brno, Brno, Czech Republic.

Eva Jandakova (E)

The Institute of Pathology, The University Hospital Brno, Brno, Czech Republic.

Tomas Pavlik (T)

The Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.

Petra Kovalcikova (P)

The Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.

Tomas Kazda (T)

Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 65653, Brno, Czech Republic. tomas.kazda@mou.cz.
Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. tomas.kazda@mou.cz.

Vlastimil Valek (V)

The Clinic of Radiology and Nuclear Medicine, The University Hospital Brno, Brno, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH